Uppsala, Sweden

Helena Lindgren

This inventor holds 1 USPTO granted patent and 1 published patent application and 1 EPO patent. Top assignee: Ge Healthcare Bio-Sciences Ab. Active years: 2011.

USPTO Granted Patents = 1 


Average Co-Inventor Count = 5.0

ph-index = 1


Company Filing History:


Years Active: 2011

Loading Chart...
Loading Chart...
1 patent (USPTO):Explore Patents

Title: Helena Lindgren: Innovator in Metal Chelating Affinity Ligands

Introduction

Helena Lindgren is a prominent inventor based in Uppsala, Sweden. She has made significant contributions to the field of biochemistry, particularly in the development of metal chelating affinity ligands. Her innovative work has led to the filing of a patent that showcases her expertise and creativity in this specialized area.

Latest Patents

Helena holds a patent for a "Method for generating metal chelating affinity ligands." This invention relates to a method for generating at least one polydentate metal chelating affinity ligand, which method comprises specific steps that enhance the efficiency and effectiveness of ligand generation.

Career Highlights

Helena is associated with GE Healthcare Bio-Sciences AB, where she applies her knowledge and skills to advance research and development in healthcare technologies. Her work at GE Healthcare has positioned her as a key player in the innovation landscape of biochemistry.

Collaborations

Helena has collaborated with notable colleagues, including Andreas Axen and Jean-Luc Maloisel. These partnerships have fostered a collaborative environment that encourages the exchange of ideas and expertise, further enhancing the impact of her work.

Conclusion

Helena Lindgren's contributions to the field of metal chelating affinity ligands exemplify her innovative spirit and dedication to advancing biochemistry. Her patent and collaborations reflect her commitment to improving healthcare technologies through scientific innovation.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to [email protected]
Loading…